Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma.
Wenqing JiaZhuoran LiuLing ZhanQiwu ZhaoWeihua QiuJie KuangPublished in: Journal of clinical medicine (2022)
Thyroid cancer (TC) is the most prevalent endocrine malignancy, with a rising incidence in the past decade [...].
Keyphrases